Lupin Expands GLP-1 Portfolio with Galenicum Semaglutide Deal

“Our partnership with Galenicum marks a strategic milestone in strengthening Lupin’s Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major public health priority, Semaglutide stands out as a critical therapy,” said Fabrice Egros, President, Corporate Development, Lupin. He added that Lupin’s established commercial footprint across key global markets positions the company to scale access to GLP-1 therapies and reinforce its commitment to affordable, high-quality medicines.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, helps regulate blood sugar levels and appetite. It is primarily prescribed for adults with Type 2 diabetes, alongside diet and exercise, and is also used for long-term weight management in adults with obesity or overweight conditions.

Commenting on the collaboration, Joaquim Domingo, Co-founder of Galenicum, said the partnership aligns with the company’s strategy to scale high-impact volumes of Semaglutide globally. He noted that Galenicum has made significant investments in its GLP-1 development pipeline to address the growing global demand for these therapies, with the aim of becoming a leading B2B player in the GLP-1 segment.

The agreement adds to Lupin’s recent efforts to expand its global GLP-1 portfolio and follows a series of strategic licensing partnerships aimed at strengthening its position in complex and high-growth therapeutic segments.